Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG017 in Postmenopausal Women With Stress Urinary Incontinence
NCT05674045Phase 2Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EG-017 in stress urinary incontinence (SUI) (4 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Percent change in urinary incontinence volume measured in a 1-hour pad test at 12 weeks. Started Jan 2022; status: completed.
02
Drugs
EG-017
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT05674045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674045.